European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
出版年份 2022 全文链接
标题
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
作者
关键词
-
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-06-11
DOI
10.1186/s10194-022-01431-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
- (2022) Takao Takeshima et al. JOURNAL OF HEADACHE AND PAIN
- Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey
- (2022) Austėja Dapkutė et al. NEUROLOGICAL SCIENCES
- Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
- (2022) Peter Holzer et al. Frontiers in Physiology
- Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
- (2022) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
- (2022) Linda Al-Hassany et al. LANCET NEUROLOGY
- Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database
- (2021) Roberta Noseda et al. CEPHALALGIA
- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
- (2021) Dulanji K. Kuruppu et al. ADVANCES IN THERAPY
- Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
- (2021) Maria Michela Cainazzo et al. NEUROLOGICAL SCIENCES
- Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
- (2021) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
- (2021) Todd J. Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
- (2021) Ilana D. Breen et al. JAMA Network Open
- Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
- (2021) Shuu-Jiun Wang et al. CEPHALALGIA
- Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series
- (2021) Ignacio Patier Ruiz et al. EUROPEAN NEUROLOGY
- Timing and durability of response to erenumab in patients with chronic migraine
- (2021) Stewart J. Tepper et al. HEADACHE
- Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
- (2021) Takao Takeshima et al. HEADACHE
- Predictors of response to erenumab after 12 months of treatment
- (2021) Carlo Baraldi et al. Brain and Behavior
- Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
- (2021) Agaath Hedina Manickam et al. Clinical Case Reports
- Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
- (2021) Uwe Reuter et al. CEPHALALGIA
- Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
- (2021) Lucas Hendrik Overeem et al. CEPHALALGIA
- Timing and durability of response to erenumab in patients with episodic migraine
- (2021) Peter J. McAllister et al. HEADACHE
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
- (2021) Peter McAllister et al. JOURNAL OF HEADACHE AND PAIN
- Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
- (2021) Andreas Straube et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
- (2021) Fenne Vandervorst et al. JOURNAL OF HEADACHE AND PAIN
- Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
- (2021) Hisaka Igarashi et al. Journal of Pain Research
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
- (2020) Kristian Agmund Haanes et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
- (2020) Inge A. Mulder et al. ANNALS OF NEUROLOGY
- Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab
- (2020) Ilaria Frattale et al. Internal and Emergency Medicine
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
- (2020) Stephen D. Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
- (2020) Hans‐Christoph Diener et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
- (2019) Valentina Favoni et al. JOURNAL OF HEADACHE AND PAIN
- Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
- (2019) Peter J Goadsby et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Raynaud's Phenomenon Associated With Calcitonin Gene‐Related Peptide Monoclonal Antibody Antagonists
- (2019) Randolph W. Evans HEADACHE
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine
- (2019) Jeanine L. Bussiere et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
- (2019) Fumihiko Sakai et al. HEADACHE
- Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
- (2019) Holland C. Detke et al. HEADACHE
- Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2019) Paul K. Winner et al. HEADACHE
- Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class
- (2019) Christian Ziegeler et al. HEADACHE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
- (2018) Christophe Depre et al. HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Wiping Out CGRP: Potential Cardiovascular Risks
- (2016) Antoinette MaassenVanDenBrink et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?
- (2015) JA Pijpers et al. CEPHALALGIA
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study
- (2014) Sonali Yadav et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search